Ibrutinib therapy for patients with relapsed or refractory mantle cell lymphoma: A budget impact analysis from a U.S. payer perspective.

e19553 Background: In the US approximately 4,000 incident cases of mantle cell lymphoma (MCL) and 1,000 attributed deaths occur annually. Management of relapsed/refractory (R/R) MCL is challenging,...